Dual ACE and Neutral Endopeptidase InhibitorsNovel Therapy for Patients with Cardiovascular Disorders

被引:0
|
作者
Reza Tabrizchi
机构
[1] Memorial University of Newfoundland,Division of Basic Medical Sciences, Faculty of Medicine
[2] Health Sciences Centre,undefined
来源
Drugs | 2003年 / 63卷
关键词
Enalapril; Brain Natriuretic Peptide; Atrial Natriuretic Peptide; Lisinopril; HCTZ;
D O I
暂无
中图分类号
学科分类号
摘要
Elevated blood pressure is a risk factor for a variety of cardiovascular disorders, including coronary heart disease, peripheral vascular disease, cardiac failure and cerebrovascular disease. The prevailing view is that an elevated systolic rather than diastolic blood pressure is the major contributor in mortality and morbidity attributed to cardiovascular disorders. Isolated high systolic blood pressure, especially in the elderly, is a major risk factor and should undoubtedly be a target for drug treatment. In the general population, systolic and diastolic blood pressure are highly correlated, and thus it is difficult to dissociate the effects of these two components of the blood pressure and specifically ascribe cardiovascular risk factors to just elevated systolic blood pressure. Therefore, the goal in therapy of an individual with hypertension must be to reduce elevated systolic and diastolic blood pressure in order to reduce mortality and morbidity.
引用
收藏
页码:2185 / 2202
页数:17
相关论文
共 50 条
  • [1] Dual ACE and neutral endopeptidase inhibitors - Novel therapy for patients with cardiovascular disorders
    Tabrizchi, R
    [J]. DRUGS, 2003, 63 (20) : 2185 - 2202
  • [2] Dual neutral endopeptidase (NEP) Angiotensin Converting Enzyme (ACE) inhibition is biologically different from ACE inhibition, at the same level of ACE inhibition
    Massien, C
    Azizi, M
    Guyene, TT
    Ménard, J
    [J]. JOURNAL OF HYPERTENSION, 1998, 16 : S235 - S235
  • [3] Effect of dual inhibition of angiotensin converting enzyme (ACE) and neutral endopeptidase (NEP) on coronary microvasculature in SHR.
    Pu, Q
    Larouche, I
    Schiffrin, EL
    [J]. CIRCULATION, 2001, 104 (17) : 22 - 22
  • [4] CCB/ACE inhibitor dual therapy for hypertension lowers cardiovascular risk
    Mitka, Mike
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (19): : 2263 - 2264
  • [5] Comparison of angiotensin converting enzyme (ACE), neutral endopeptidase (NEP), and dual ACE/NEP inhibition on cardiac and renal fibrosis in DOCA-salt hypertensive rats
    Pu, D
    Gannon, P
    Schiffrin, EL
    [J]. HYPERTENSION, 2002, 40 (03) : 414 - 414
  • [6] Bradykinin metabolism in the postinfarcted rat heart: role of ACE and neutral endopeptidase 24.11
    Raut, R
    Rouleau, JL
    Blais, C
    Gosselin, H
    Molinaro, G
    Sirois, MG
    Lepage, Y
    Crine, P
    Adam, A
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 1999, 276 (05): : H1769 - H1779
  • [7] Potential role of mixed ACE and neutral endopeptidase inhibitor in the treatment of heart failure
    Hu, K
    Ertl, G
    [J]. CARDIOVASCULAR RESEARCH, 1999, 41 (03) : 503 - 505
  • [8] Neutral endopeptidase (NEP) angiotensin converting enzyme (ACE) inhibition with omapatrilat (OMA): What is beyond ACE inhibition?
    Azizi, M
    Massien, C
    Vesterqvist, O
    Gielsdorf, W
    Liao, WC
    Mangold, B
    Menard, J
    [J]. CIRCULATION, 1998, 98 (17) : 792 - 792
  • [9] Neutral Endopeptidase (Neprilysin) in Therapy and Diagnostics: Yin and Yang
    E. E. Feygina
    A. G. Katrukha
    A. G. Semenov
    [J]. Biochemistry (Moscow), 2019, 84 : 1346 - 1358
  • [10] Neutral Endopeptidase (Neprilysin) in Therapy and Diagnostics: Yin and Yang
    Feygina, E. E.
    Katrukha, A. G.
    Semenov, A. G.
    [J]. BIOCHEMISTRY-MOSCOW, 2019, 84 (11) : 1346 - 1358